NFL Biosciences
Develops botanical drug candidates to treat smoking and alcohol addictions.
ALNFL | PA
Overview
Corporate Details
- ISIN(s):
- FR0014003XO1 (+1 more)
- LEI:
- 9695006VJWNTN4UNHA27
- Country:
- France
- Address:
- 199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
- Website:
- https://www.nflbiosciences.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead asset is NFL-101, an innovative drug candidate for smoking cessation derived from a nicotine-free protein extract of tobacco leaves. Its pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences operates with an outsourced research model, focusing on advancing its products through preclinical and clinical studies. The company's primary business strategy is to license its developed drug candidates to larger pharmaceutical companies for final commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-23 07:30 |
Share Issue/Capital Change
NFL Biosciences announces the success of its capital increase capped at €3 mill…
|
English | 311.5 KB | ||
| 2025-05-23 07:30 |
Share Issue/Capital Change
Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafo…
|
French | 304.2 KB | ||
| 2025-05-22 17:45 |
Share Issue/Capital Change
NFL Biosciences launches a capital increase of approximately €2.2 million
|
English | 354.2 KB | ||
| 2025-05-22 17:45 |
Share Issue/Capital Change
NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voi…
|
French | 310.7 KB | ||
| 2025-05-21 17:45 |
Post-Annual General Meeting Information
NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025
|
French | 151.3 KB | ||
| 2025-05-12 08:30 |
Board/Management Information
NFL Biosciences strengthens its scientific committee with world-class experts t…
|
English | 177.7 KB | ||
| 2025-05-12 08:30 |
Regulatory News Service
NFL Biosciences renforce son Comité Scientifique avec des experts de renommée m…
|
French | 175.8 KB | ||
| 2025-05-06 18:40 |
Report Publication Announcement
Assemblée générale mixte du 21 mai 2025 : modalités de mise à disposition et co…
|
French | 151.8 KB | ||
| 2025-05-05 08:30 |
Regulatory News Service
NFL Biosciences announces results from a new study conducted with the CEA provi…
|
English | 352.0 KB | ||
| 2025-05-05 08:30 |
Earnings Release
NFL Biosciences annonce les résultats d’une nouvelle étude menée avec le CEA pe…
|
French | 326.4 KB | ||
| 2025-04-24 17:45 |
Regulatory News Service
Marex Group initiates coverage of NFL Biosciences with a Buy rating
|
English | 185.7 KB | ||
| 2025-04-24 17:45 |
Regulatory News Service
Marex Group initie à l’achat la couverture de NFL Biosciences
|
French | 164.8 KB | ||
| 2025-04-15 18:00 |
Report Publication Announcement
NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2…
|
French | 179.3 KB | ||
| 2025-04-11 17:45 |
Earnings Release
NFL Biosciences presents its 2024 annual results and provides an update on its…
|
English | 346.5 KB | ||
| 2025-04-11 17:45 |
Earnings Release
NFL Biosciences présente ses résultats annuels 2024 et fait le point sur son pr…
|
French | 311.1 KB |
Automate Your Workflow. Get a real-time feed of all NFL Biosciences filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for NFL Biosciences via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
